Clinical Trial

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Study acronym: ONWARDS 11
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
Protocol Amendment History 4 changes
notable Trial sites expanded: 193 -> 196 locations 2026-06-30
notable Trial sites expanded: 184 -> 193 locations 2026-04-07
notable Primary completion pushed: 2026-11-23 -> 2027-01-25 2026-04-07
minor Completion pushed: 2026-12-28 -> 2027-03-01 2026-04-07
Trial Details
NCT Number NCT07076199
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 1
Enrollment 877 participants
Start Date 2025-08-11
Primary Completion 2027-01-25 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29